A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Maintenance Treatment Versus no Further Treatment in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) Who Have Responded to Induction Therapy
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms PROLONG
- Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
Most Recent Events
- 24 Dec 2021 This study has been completed in Belgium as per European Clinical Trials Database.
- 12 Apr 2019 Status changed from completed to discontinued.
- 10 Sep 2018 This study has been Discontinued in Netherlands.